Navigation Links
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Date:8/19/2007

Management to Make Two Presentations on the Topic of Drug Repurposing and

Indian Clinical Trial Strategy

MORRISTOWN, N.J., Aug. 16 /PRNewswire/ -- Vicus Therapeutics, Inc., an oncology-focused, clinical-stage biopharmaceutical company, announced today that Chief Executive Officer, John Maki, and Chief Scientific Officer, Frederic Young, Ph.D., will each present at the 234th American Chemical Society National Meeting on Sunday, August 19, 2007. The Meeting is being held at the Boston Convention & Exhibition Center in Boston, MA.

Dr. Young will present "Hypothesis-driven Drug Repurposing Based on a Novel Systems Biology Approach," including a discussion of Vicus' complexity theory-based drug repurposing approach in creating a pipeline of product candidates for the treatment of important unmet medical needs. The Company's approach can be applied to the discovery of product candidates for any indication, including cancer cachexia, a metabolic disorder, mucositis, a wound healing disorder, and cancer fatigue, a CNS disorder. The specific application of this method will be discussed in the context of the Company's lead compound, VT-122. Dr. Young's presentation is scheduled for 11:45 a.m.

Mr. Maki's presentation, entitled "Synergistic Advantages of Drug Repurposing and Clinical Trial Off-shoring in India", will include a discussion of the unique synergistic advantages of drug re-profiling and off- shoring, as well as an overview of the steps necessary to realize such advantages. Specifically, Mr. Maki will provide highlights from the Company's ongoing Phase 2 clinical trial of VT-122 for cancer cachexia, now being conducted in the U.S. and India. In addition, he will review recent changes by the Drug Controller General of India (DCGI, the Indian FDA-regulatory equivalent), Indian clinical research infrastructure, and the acceptance of Indian data by the U.S. Food & Drug Administration (FDA) that is currently driving the expl
'/>"/>

SOURCE Vicus Therapeutics

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... According to a new market ... Prostate) Type (Protein & Genetic Biomarkers) Profiling Technology (Proteomics, ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... 17,689.0 Million USD by 2020 at a CAGR of ... Browse 191 Tables and 38 F ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Tobramycin Market, 2010-2019" report ... antibiotic whose eye drop and ointment are the most ... or inflammation caused by eye infection. Currently, dozens of ... to produce tobramycin, among which the Top 5 are ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Insulin Aspart Market, ... Developed by Novo Nordisk, insulin aspart (under the ... for the treatment of diabetes. Compared with human ... analog, starts working fast and reports higher peak ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5Investigation Report on China's Tobramycin Market, 2015-2019 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... SOUTH SAN FRANCISCO, Calif., May 6 Exelixis,Inc. ... for the first quarter,ended March 31, 2008., ... were $27.9 million,compared to $28.1 million for the ... consistent with 2007, but reflect the completion of,revenue ...
... DIEGO, May 6 TriLink BioTechnologies (TriLink), ... has been awarded a,Phase II Small Business ... continue its investigation of modified dNTPs to ... studies demonstrated that TriLink,s,unique dNTP modifications enhanced ...
Cached Medicine Technology:Exelixis Announces First Quarter 2008 Financial Results 2Exelixis Announces First Quarter 2008 Financial Results 3Exelixis Announces First Quarter 2008 Financial Results 4Exelixis Announces First Quarter 2008 Financial Results 5Exelixis Announces First Quarter 2008 Financial Results 6TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project 2
(Date:8/28/2015)... ... August 28, 2015 , ... An article ... pizza maker Paul LaRocco has gone through to open a pizzeria in Westchester. Mr. ... process tends to take several months, but the current process, having already gone on ...
(Date:8/28/2015)... ... ... For Dallas, the time is nearing for the annual Heart Walk, and North ... American Heart Association hosts their well-known Heart Walk to raise money in awareness and ... be made. Walkers can participate in the cause and someone can also donate, even ...
(Date:8/28/2015)... Baltimore, MD (PRWEB) , ... August 28, 2015 , ... ... reduction system from Merz, received FDA clearance for results that last for two ... clearance is exciting news for patients who are looking for a long-lasting, effective solution ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, Best Drug ... of the “Music With A Mission” benefit concert in Mendon, IL. Held in the ... raise money to support music education programs in the underfunded local school districts of ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, ... fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch ... CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected ...
Breaking Medicine News(10 mins):Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... impact predicted to be mild , TUESDAY, Dec. 8 (HealthDay ... impact of the H1N1 swine flu pandemic during the autumn-winter ... , "As more detailed data have become available, we ... this disease is. Early on, it was difficult to measure ...
... following was released today by Randall Terry, Director, Operation Rescue ... team members will travel to 13 Cathedrals in 9 states ... at the Boston Cathedral, the seat of Cardinal O,Malley, the ... Kerry families. , They will ask Catholic Bishops: "Your ...
... ... MDRX ) Chief Executive Officer Glen Tullman will host a webcast ... to introduce two new innovations: Allscripts Professional(TM) EHR 9.0 ... Record for small- and medium-sized physician groups; and Allscripts Remote ...
... HUNTINGTON BEACH, California and AMSTERDAM, December 8 ,Agendia, ... will be presenting six studies focusing on MammaPrint(R) at the ... conferences in,breast cancer research worldwide. The SABCS will take place ... Antonio, Texas, USA. , Agendia,s studies ...
... , CINCINNATI, Dec. 8 ... leading provider of document workflow solutions for hospitals, today announced ... technology to improve quality and operating efficiency by providing their ... their healthcare enterprise. The implementation of the Company,s enterprise ...
... YORK, Dec. 8 Parenting a family of any size or ... is that in this "second family," the parenting does not involve ... , According to William Bryan, Ph.D., cofounder of Active Seniors ... define this particular phenomenon that affects 10 million households where an ...
Cached Medicine News:Health News:Swine Flu Pandemic May Be Less Severe Than Expected 2Health News:Abortion, Bishops, and Healthcare: Announcing 'Deaf at the Cathedral' Tour in Nine States. 2Health News:Allscripts Launches New Innovations in Live Event 2Health News:Allscripts Launches New Innovations in Live Event 3Health News:Allscripts Launches New Innovations in Live Event 4Health News:Allscripts Launches New Innovations in Live Event 5Health News:Allscripts Launches New Innovations in Live Event 6Health News:Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium 2Health News:Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium 3Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 2Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 3Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 4Health News:'Sandwich Generation' Avoids Unnecessary Stress While Tending to Aging Senior Parents 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: